Healthcare / Diagnostics & ResearchNasdaqGM
$15.27
-1.05 (-6.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-45.9M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$158M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1430.6%
↑Gross Margin
81.1%
↑Debt/Equity
-29.56
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+23.8%
FCF CAGR
—
FCF margin
-26.8%
FCF / Net income
0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $88.5M · net income $-35.3M · FCF $-23.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $88.5M | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M | $45.6M | $24.6M |
| Net Income | $-35.3M | $-35.3M | $-42.9M | $-52.1M | $-65.4M | $-43.2M | $-65.4M | $-30.7M |
| EBITDA | $-21.9M | $-21.9M | $-29.2M | $-37.1M | $-51.5M | $-37.8M | $-20.0M | $-23.9M |
| EPS | -4.67 | -4.67 | -6.60 | -12.80 | -31.00 | -31.60 | — | — |
| Gross Margin | 81.1% | 81.1% | 78.2% | 73.5% | 63.0% | — | — | — |
| Operating Margin | -31.4% | -31.4% | -48.0% | -84.1% | -132.2% | -75.1% | -50.3% | -108.9% |
| Net Margin | -39.8% | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% | -143.7% | -125.1% |
| Balance Sheet | ||||||||
| Debt/Equity | -29.56 | -29.56 | 2.97 | 13.25 | 1.55 | 0.51 | 0.68 | — |
| Current Ratio | 2.82 | 2.82 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-23.7M | $-23.7M | $-52.1M | $-45.9M | $-48.5M | $-30.5M | $-23.3M | $-23.0M |
| Returns | ||||||||
| ROE | 1430.6% | 1430.6% | -205.6% | -1138.6% | -317.6% | -218.8% | -159.0% | 13.6% |
| Valuation | ||||||||
| P/B | — | — | 9.19 | 35.32 | 4.45 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 24.1% | 24.1% | 45.3% | 28.5% | — | 19.6% | 85.6% | — |
| EPS Growth | 29.2% | 29.2% | 48.4% | 58.7% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+152.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.60 → -4.67
Residual
+152.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.